Phase III Dasatinib data demonstrates efficacy in Imatinib Resistant CML

Phase III clinical data shows Dasatinib to demonstrate efficacy in chronic phase Imatinib Resistant and intolerant chronic myelogenous leukemia (CML)

Phase II data shows Sorafenib to demonstrate efficacy in advanced thyroid cancer

Phase II data show sorafenib to demonstrate efficacy in patients with advanced thyroid carcinoma. The overall clinical benefit rate (partial response + stable disease) was 77% and the drug had an acceptable safety profile.

CytRx to Acquire Innovive Pharmaceuticals

CytRx have signed a definitive agreement to acquire Innovive Pharmaceuticals. Innovive currently has a dual Bcr-Abl and Lyn-kinase inhibitor INNO-406 (formerly known as NS-187) in Phase I trials in Gleevec resistant CML

Astex collaborate with Janssen on FGFR inhibitors

Janssen have formed a worldwide licensing collaboration with Astex granting them access to Astex’s FGFR inhibitor program as well as two other undisclosed programs. The deal is worth over $37 million in upfront payments, cash and equity payments and research funding with future milestome payments that could total more than $500 million.

Pharmacyclics Btk inhibitor shows efficacy in RA and Lymphoma

Data presented at Federation of Clinical Immunology Societies (FOCIS) meeting show Pharmacyclics’ BTK inhibitor PCI-32765 to have demonstrated efficacy in a model of collagen induced arthritis. PCI-32765 was found to reduce inflammation and inducee regression of the disease.